Bloodstream infection and occlusion of central venous catheters in children

The Lancet Infectious Diseases

Volumn 18, Issue 8, 2018, Pages 815-817

  Rickard, Claire M ^a   Ullman, Amanda J ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ALCOHOL;

BLOODSTREAM INFECTION; CATHETER INFECTION; CATHETER OCCLUSION; CHILD; DEVICE REMOVAL; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BACTEREMIA; CENTRAL VENOUS CATHETER; CENTRAL VENOUS CATHETERIZATION; DOUBLE BLIND PROCEDURE; NEOPLASM;

BACTEREMIA; CATHETER-RELATED INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; CENTRAL VENOUS CATHETERS; CHILD; DOUBLE-BLIND METHOD; ETHANOL; HUMANS; NEOPLASMS;

EID: 85048570862     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(18)30267-6     Document Type: Note

References (13)

1. Ullman, AJ, Marsh, N, Mihala, G, Cooke, M, Rickard, CM, Complications of central venous access devices: a systematic review. Pediatrics 136 (2015), e1331–e1344.
2. Journeycake, JM, Buchanan, GR, Catheter-related deep venous thrombosis and other catheter complications in children with cancer. J Clin Oncol 24 (2006), 4575–4580.
3. Wolf, J, Connell, TG, Allison, KJ, et al. Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial. Lancet Infect Dis, 2018 published online June 5. http://dx.doi.org/10.1016/S1473-3099(18)30224-X.
4. US CDC. Chapter 4: bloodstream infection event (central line-associated bloodstream infection and non-central line-associated bloodstream infection). National Healthcare Safety Network (NHSN) patient safety component manual, 2017, US Centers for Disease Control and Prevention, Atlanta, GA, 1–38.
5. Kato, Y, Hagihara, M, Kurumiya, A, et al. Impact of mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) on central line-associated bloodstream infections (CLABSIs) in department of hematology at single university hospital in Japan. J Infect Chemother 24 (2018), 31–35.
6. Mermel, LA, Allon, M, Bouza, E, et al. Clinical practice guidelines for diagnosis & management of intravascular catheter-related infection: 2009 updated by the Infectious Diseases Society of America. Clin Infect Dis 49 (2009), 1–45.
7. Taylor, JE, Tan, K, Lai, NM, McDonald, SJ, Antibiotic lock for the prevention of catheter-related infection in neonates. Cochrane Database Syst Rev, 6, 2015 CD010336.
8. Huang, E, Chen, C, Abdullah, F, et al. Strategies for the prevention of central venous catheter infections: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review. J Pediatr Surg 46 (2011), 2000–2011.
9. Simon, A, Ammann, RA, Wiszniewsky, G, Bode, U, Fleischhack, G, Besuden, MM, Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated Gram positive infections in pediatric cancer patients. BMC Infect Dis 8 (2008), 1–8.
10. Ullman, AJ, Cooke, M, Mitchell, M, et al. Dressings and securement devices for central venous catheters (Review). Cochrane Database Syst Rev, 9, 2015 CD010367.
11. Shah, PS, Shah, N, Heparin-bonded catheters for prolonging the patency of central venous catheters in children. Cochrane Database Syst Rev, 2, 2014 CD005983.
12. Ista, E, van der Hoven, B, Kornelisse, RF, et al. Effectiveness of insertion and maintenance bundles to prevent central-line-associated bloodstream infections in critically ill patients of all ages: a systematic review and meta-analysis. Lancet Infect Dis 16 (2016), 724–734.
13. Bradford, NK, Edwards, RM, Chan, RJ, Heparin versus 0·9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children. Cochrane Database Syst Rev, 11, 2015 CD010996.